Andrew Moreno

DocwireNews

Oral ivosidenib monotherapy shows promise in mutant IDH1 myelodysplastic syndromes (MDS), according to final results data from the phase II IDIOME trial. Researchers reported the data at the European Hematology Association 2024 Hybrid Congress in Madrid, Spain.&ldquo;Ivosidenib monotherapy was associated with significant responses in all mutant IDH1 MDS patient cohorts and, in this frail population, was well tolerated,&rdquo; the trial investigators summarized.The total IDIOME study cohort included 48 patients, was 50% female, and had a median age of 76.5 years. Patients were divided into three cohorts, and patients in all cohorts received continuous 28-day cycles of ivosidenib 500 mg once daily.The first cohort comprised 22 patients with high-risk disease in whom prior azacitidine therapy had been unsuccessful. An overall hematological response after three cycles was achieved in 63.6% of these patients, and the median duration of response was 4.8 months. The median overall survival (OS) was 8.9 months, and the 12.0-month OS rate was 15.2%.The second cohort included 23 patients with high-risk disease receiving ivosidenib as first-line treatment. If these patients had no response after three cycles of ivosidenib, they were administered azacitidine. An overall hematological response after three cycles was achieved in 78.3%, and the 12-month OS rate was 91.3%. Azacitidine was added in three patients and did not produce an additional response.&ldquo;The high overall hematological response rate and prolonged [OS] observed in treatment-naive high-risk MDS patients suggest that ivosidenib monotherapy could be a first-line treatment in this population, including in candidates for hematopoietic stem cell transplantation,&rdquo; the investigators added regarding results from the second cohort.The third cohort comprised three patients with low-risk disease and in whom prior erythropoietin therapy had been unsuccessful. Two patients achieved complete response and had no disease progression as of the study&rsquo;s conclusion. The third patient died two years after study inclusion following 13 cycles of treatment.Regarding safety findings, 21 treatment-related adverse events were reported by nine patients. Most of these events were differentiation syndrome, and all were reversible.ReferenceS&eacute;bert M, Clappier E, Cluzeau T, et al. Ivosidenib monotherapy in IDH1 mutated myelodysplastic syndrome, final results of the IDIOME trial, a GFM study. Abstract #S182. Presented at the European Hematology Association 2024 Hybrid Congress; June 13-16, 2024; Madrid, Spain.

Jordana Jampel

Brensocatib Shows Positive Results for Managing Bronchiectasis Symptoms

Pulmonology

Areef Ishani, MD

Joel M. Topf, MD, FACP

Kidney Stones With Chlorthalidone Versus Hydrochlorothiazide

NKF Spring Clinical Meetings 2025

MarkAlain Déry, DO

Eric Griggs, MD

Measles in America: An Ongoing Problem

Infectious Disease

Latest News

Oral Monotherapy Produces Significant Response in IDH1-Mutated MDS

Final data from a phase II trial suggest a promising option for elderly patients with this serious disease.

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe